Chronic Prostatitis vs. BPH: How to Tell the Difference

Prostatitis and BPH affect the same organ but involve entirely different processes. BPH is a structural growth of transition zone tissue — glandular and stromal cells proliferating to create bulk that obstructs the urethra. Prostatitis is inflammation of the prostate — immune cells, inflammatory mediators, and in some cases bacteria — creating swelling, pain, and urinary symptoms through irritation rather than mechanical obstruction.

The Key Diagnostic Difference: Pain

Pain is the most reliable differentiating feature. BPH does not cause pain — it causes obstruction symptoms (weak stream, hesitancy, incomplete emptying, frequency). Prostatitis typically involves pelvic pain — perineal aching, testicular discomfort, lower abdominal pressure, or pain on ejaculation. If a man has urinary symptoms WITH pelvic pain, prostatitis (or a combination) should be the primary diagnostic consideration.

The 4 NIH Categories of Prostatitis

• •Category I — Acute bacterial prostatitis: Sudden onset, fever, perineal pain, dysuria. Requires urgent antibiotic treatment. Rare.
• •Category II — Chronic bacterial prostatitis: Recurrent UTIs with same organism, milder symptoms between episodes. Requires prolonged antibiotics.
• •Category III — Chronic pelvic pain syndrome (CPPS): Most common (90% of cases). No infection identified. Subdivided into IIIa (inflammatory) and IIIb (non-inflammatory). Complex, multifactorial management.
• •Category IV — Asymptomatic inflammatory prostatitis: Found incidentally on biopsy or elevated PSA. No symptoms — no treatment required.

Age Distribution

BPH overwhelmingly affects men over 50. Chronic prostatitis/CPPS predominantly affects men aged 25–50. A man under 45 with urinary symptoms and any pelvic pain should be evaluated primarily for prostatitis, not BPH — though both can coexist.

Diagnosis: How Doctors Tell Them Apart

The diagnostic workup differs significantly between BPH and prostatitis. For BPH: IPSS questionnaire, PSA, PVR measurement by bladder scan, urine flow rate (Qmax), and transrectal ultrasound for prostate volume form the standard evaluation. For prostatitis: the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) is the validated scoring tool, assessing pain location and severity, voiding symptoms, and quality of life impact. Expressed prostatic secretions (EPS) analysis and segmented urine cultures (the Meares-Stamey 4-glass test or simplified 2-glass test) help classify between categories II, IIIa, and IIIb. Crucially, prostatitis does not require elevated PSA — and elevated PSA in the context of prostatitis symptoms should trigger repeat testing after resolution rather than immediate biopsy.

Treatment Differences: BPH vs. Prostatitis

• •Bacterial prostatitis (Cat I and II): Fluoroquinolone antibiotics (ciprofloxacin or levofloxacin) for 4–6 weeks for chronic form. Category I requires hospitalisation and IV antibiotics initially. Alpha-blockers added to reduce obstructive voiding symptoms during treatment.
• •CPPS Category III (most common): No single effective treatment — multimodal approach required. Alpha-blockers reduce voiding symptoms. Anti-inflammatory agents (NSAIDs, quercetin) address the inflammatory component. Pelvic floor physiotherapy for myofascial trigger points. Psychological support for central sensitisation.
• •BPH: Alpha-blockers (first-line), 5-ARIs for large glands, combination therapy, progressing to minimally invasive procedures (UroLift, Rezūm) or TURP if medication fails.
• •Key difference: antibiotics have no role in BPH treatment. Surgical procedures (TURP) have no role in pure prostatitis treatment.

Prostatitis Symptom Scoring: The NIH-CPSI

The NIH Chronic Prostatitis Symptom Index (NIH-CPSI) provides a validated framework for quantifying prostatitis severity across three domains: pain (scored 0–21), urinary symptoms (scored 0–10), and quality of life impact (scored 0–12). Total score ranges from 0–43; mild: 0–14, moderate: 15–29, severe: 30–43. Unlike the IPSS (which focuses entirely on voiding function), the NIH-CPSI captures the pain and life impact dimensions that define prostatitis. Men with both conditions require both scoring tools to fully characterise their symptom burden.

When Prostatitis and BPH Coexist: Clinical Complexity

When both conditions are present simultaneously, treatment sequencing matters. Controlling active prostatitis inflammation first often produces meaningful BPH symptom improvement, as prostatic swelling from inflammation adds to the mechanical obstruction of BPH. Treating BPH with alpha-blockers improves urinary flow and reduces bladder pressure that can worsen prostatitis pain. The NIH-CPSI and IPSS scores should be tracked independently — allowing the clinician to see which condition is dominating the symptom picture at each point in treatment and adjust accordingly.

The NIH Classification of Prostatitis

The NIH classification system divides prostatitis into four distinct categories. Type I is acute bacterial prostatitis — dramatic onset with fever, rigors, and severe urinary symptoms caused by bacterial infection. Type II is chronic bacterial prostatitis — recurrent urinary tract infections with a bacterial reservoir in the prostate, often caused by Gram-negative organisms. Type IIIA is chronic non-bacterial inflammatory prostatitis — white blood cells in expressed prostatic secretions but no culturable bacteria. Type IIIB is chronic non-bacterial non-inflammatory prostatitis, also called chronic pelvic pain syndrome (CPPS) — the most common type, characterised by pelvic pain without either bacteria or white cells. Type IV is asymptomatic inflammatory prostatitis — an incidental finding.

How to Distinguish Prostatitis from BPH

• •Age of onset: prostatitis is more common in younger and middle-aged men; BPH predominantly affects men over 50, with prevalence rising with age
• •Pain: prostatitis characteristically produces perineal, suprapubic, penile, or scrotal pain — often deep and difficult to localise; BPH does not cause pain unless complicated by AUR or infection
• •Ejaculatory symptoms: painful ejaculation (dysorgasmia or post-ejaculatory pain) is a hallmark of prostatitis and is absent in uncomplicated BPH
• •Urinary symptoms: both cause dysuria and frequency, but BPH predominantly produces obstructive symptoms (weak stream, hesitancy, incomplete emptying) while prostatitis more prominently produces irritative symptoms (urgency, frequency, dysuria)
• •PSA: acutely elevated in bacterial prostatitis — sometimes above 100 ng/mL — returning to baseline after treatment; moderately elevated in chronic prostatitis; chronically elevated in proportion to prostate volume in BPH

PSA in Prostatitis: A Critical Warning

Prostate-specific antigen rises dramatically during acute bacterial prostatitis due to disruption of the glandular epithelial barrier. A PSA drawn during active prostatitis is not interpretable for cancer risk and must never prompt a prostate biopsy. Biopsy during active infection risks seeding bacteria into the bloodstream (septicaemia). Any man with an unexpectedly high PSA should be asked about recent urinary symptoms, fever, and dysuria before proceeding to biopsy. Standard practice is to treat the prostatitis, wait 6–8 weeks for PSA to normalise, then re-draw the PSA to assess residual elevation.

Treatment Differences Between Prostatitis Types and BPH

Type I and II prostatitis require antibiotics — fluoroquinolones (ciprofloxacin) or trimethoprim, chosen for good prostatic penetration. Acute bacterial prostatitis may require hospitalisation and IV antibiotics. CPPS (Type IIIB) has no single effective treatment — evidence supports alpha-blockers (improving urinary symptoms), pelvic floor physiotherapy (addressing myofascial tension, particularly in men with concurrent hypertonic pelvic floor), and psychological support (catastrophising worsens pain severity). BPH is treated with alpha-blockers (for dynamic obstruction), 5-ARIs (for volumetric reduction), and surgical options for refractory cases. The two conditions share alpha-blocker treatment but have entirely different pathophysiology.